IRADIMED CORPORATION announced record revenue of $18.3 million for Q3 2024, an 11% increase compared to Q3 2023. GAAP diluted EPS was reported as $0.40 and Non-GAAP diluted EPS as $0.43. The company is raising year-end guidance on GAAP diluted earnings per share to $1.49 to $1.52 and Non-GAAP diluted earnings per share to $1.64 to $1.67.
Record revenue of $18.3 million for the third quarter of 2024, an 11% increase year-over-year.
GAAP diluted EPS of $0.40 and Non-GAAP diluted EPS of $0.43 for the third quarter of 2024.
Year-end guidance raised for GAAP diluted earnings per share to $1.49-$1.52 and Non-GAAP diluted earnings per share to $1.64-$1.67.
Declared a regular quarterly cash dividend of $0.15 per common share for the fourth quarter of 2024.
For Q4 2024, IRADIMED anticipates revenue between $18.8 million and $19.2 million, GAAP diluted earnings per share of $0.39 to $0.42, and Non-GAAP diluted earnings per share of $0.42 to $0.45. For the full year 2024, revenue is expected to be $72.7 million to $73.1 million, with GAAP diluted earnings per share of $1.49 to $1.52, and Non-GAAP diluted earnings per share of $1.64 to $1.67.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance